Finance1 min read

SELLAS Life Sciences shares plunge 19%: What triggered the sharp sell-off?

By · Published by Everything Blog

In short

SELLAS Life Sciences priced 11.54 million new shares at $13 each, representing a steep discount to its prior closing price. The move triggered a sharp retreat despite momentum from the Phase 3 REGAL trial, where galinpepimut-S reduced the risk of death by 41% in leukemia patients. Gross proceeds could reach approximately $172.5 million if underwriters exercise their 30-day option to buy 1.73 million additional shares. The company plans to use the capital to support clinical programs and prepare for an anticipated regulatory submission by 2027.

Key points

  • Dilution concerns rapidly undercut recent stock gains that were fueled by a 150% rally on…: Dilution concerns rapidly undercut recent stock gains that were fueled by a 150% rally on positive leukemia trial results.
  • Total gross proceeds from the equity sale could rise to roughly $172.5 million ahead of t…: Total gross proceeds from the equity sale could rise to roughly $172.5 million ahead of the November 20 closing date.
  • SELLAS plans to meet with the FDA and expects to file a Biologics License Application in…: SELLAS plans to meet with the FDA and expects to file a Biologics License Application in the first half of 2027.

Sources checked by our analysis pipeline: 1

Shares of SELLAS Life Sciences Group (NASDAQ: SLS) plunged nearly 20% in overnight trading after the biotechnology company announced a discounted $150 million share offering. The sell-off came just a day after the stock rallied sharply on positive topline results from its late-stage leukemia vaccine trial. (Sources: TradingView, Yahoo Finance)

ETMarkets.com

2/5

$150 million share sale triggers investor concerns

SELLAS priced its public offering of 11.54 million new shares at $13 apiece, raising approximately $150 million in gross proceeds. The offer price represented a discount of around 28% to the stock's previous closing price of $17.95, triggering concerns over dilution among existing shareholders.

ETMarkets.com

3/5

Additional shares could increase dilution

The company also granted underwriters a 30-day option to purchase up to 1.73 million additional shares at the offering price. If fully exercised, the transaction could generate gross proceeds of approximately $172.5 million. The offering was expected to close on November 20, subject to customary conditions.

ETMarkets.com

4/5

Strong leukemia trial results had sent shares soaring

The latest decline followed a massive rally after SELLAS announced positive topline results from…

Finance